



Adalimumab Biosimilar / Interchangeable Approvals, Applications and Anticipated Launch Dates*

Biosimilar Name	Approval Date	Approved Concentration	Launch Date	Interchangeable?
Amjevita™ (adalimumab-atto)	9/23/2016	Low; High concentration in development	1/31/2023	No; Interchangeability clinical trial in progress (high concentration)
Cyltezo® (adalimumab-abdm)	8/25/2017 (Biosimilar) 10/15/2021 (Interchangeable)	Low	As early as 7/1/2023	Yes
Hyrimoz™ (adalimumab-adaz)	10/30/2018	Low; sBLA for high concentration pending	As early as 9/30/2023	No
Hadlima™ (adalimumab-bwwd)	7/23/2019 (Low) 8/17/2022 (High)	Low and High	As early as 7/1/2023	No; Interchangeability clinical trial in progress (high concentration)
Abrilada™ (adalimumab-afzb)	11/15/2019	Low	As early as 7/1/2023	sBLA for interchangeability pending
Hulio® (adalimumab-fkjp)	7/6/2020	Low	As early as 7/31/2023	No
Yusimry™ (adalimumab-aqvh)	12/17/2021	Low; High concentration in development	As early as 7/1/2023	No
Idacio® (adalimumab-aacf)	12/13/2022	Low	As early as 7/1/2023	No
AVT02 (adalimumab)	aBLA Pending	High	As early as 7/1/2023 if approved	sBLA for interchangeability pending
Yuflyma™ (adalimumab)	aBLA Pending	High	As early as 7/1/2023 if approved	No; Interchangeability clinical trial in progress

*Based on publicly available information